Anastrozol

When ATH:
L02BG03

Characteristic.

The antitumor agent, selective non-steroidal aromatase inhibitor.

The white crystalline powder. Solubility in water 0,25 mg / ml (at 25 °C), It does not depend of pH in the physiological range. Very slightly soluble in methanol, ethanol, acetone, tetrahydrofuran. Easily soluble in acetonitrile. Molecular weight 293,4.

Pharmacological action.
Antitumor.

Application.

Estrogen-dependent breast cancer in postmenopausal women with disease progression on tamoxifen or other anti-estrogens.

Contraindications.

Hypersensitivity, estrogen dependent mammary tumors in premenopausal women period, abnormalities in the liver and kidneys (creatinine clearance <20 ml / min), pregnancy, lactation.

Restrictions apply.

Estrogensoderjath drugs should not be administered concurrently with anastrozole, they would unnecessarily reduce its activity.

Pregnancy and breast-feeding.

Category actions result in FDA - X. (Animal tests or clinical trials revealed a violation of the fetus and / or there is evidence of the risk of adverse effects on the human fetus, obtained in research or practice; risk, associated with the use of drugs in pregnancy, greater than the potential benefits.)

Side effects.

From the nervous system and sensory organs: asthenic syndrome, insomnia, drowsiness, anxiety, depression, headache, dizziness, paraesthesia.

Cardio-vascular system and blood (hematopoiesis, hemostasis): anemia, hypertension (severe dizziness, long-lasting headache), leukopenia with / without infection, tromboflebit, thromboembolism.

From the respiratory system: dyspnoea, sinusitis, rhinitis, bronchitis, pharyngitis.

From the digestive tract: decreased appetite, nausea, vomiting, constipation / diarrhea, dry mouth.

Allergic reactions: incl. rash, itch, erythema multiforme, Stevens-Johnson syndrome.

Other: tides, vaginal dryness, vaginal bleeding, myalgia, arthralgia, chest pain, backache, reduction in joint mobility, Sweating, flu-like symptoms, peripheral edema, istonchenie Volos and alopecia, hypercholesterolemia, increased levels of alkaline phosphatase, IS ALT (in patients with liver metastases), weight gain.

Cooperation.

Reduces the effectiveness of estrogen. In a joint application and tamoksimfena anastrozole in patients with breast cancer decreased plasma concentrations of anastrozole on 27% as compared to that when receiving only anastrozole (co-administration did not affect the pharmacokinetics of tamoxifen and N-dezmetiltamoksifena).

Dosing and Administration.

Inside, 1 mg 1 once a day. The course of treatment depends on the type and severity of the disease.

Precautions.

In case of doubt in the hormonal menopausal status should be confirmed by biochemical studies.